ScreenerHero

MGNXMacroGenics, Inc.

NAS · US · Healthcare · Biotechnology · macrogenics.com
4.100USD-1.68%Mkt Cap: 261.17M $P/E: —

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pip…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap261.17M $
Enterprise Value121.05M $
Revenue (TTM)175.14M $
Gross Profit113.49M $
Net Income (TTM)-74.62M $
Revenue/Share2.763 USD
Last Price4.100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees293
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS5560991094
Valuation
P/E (Trailing)—
P/E (Forward)-3.57
PEG—
EV/EBITDA-3.76
EV/Revenue0.69
P/S1.48
P/B6.04
EPS (TTM)-1.55
EPS (Forward)-1.14
52W Range
1.29074% of range5.080
52W High5.080 USD
52W Low1.290 USD
Profitability
Gross Margin75.91%
Oper. Margin-42.19%
EBITDA Margin-18.37%
Profit Margin-49.91%
ROE-134.23%
ROA-29.05%
Growth
Revenue Growth378.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.04M $
CapEx (TTM)1.91M $
FCF Margin-39.63%
FCF Yield-26.58%
Net Debt-138.21M $
Net Debt/EBITDA4.30
Balance Sheet
Debt/Equity0.66
Current Ratio2.96
Quick Ratio2.92
Book Value/Sh0.6740 USD
Cash/Share2.721 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.250 USD
Upside (mean)+76.8%
Target Range4.000 USD – 11.00 USD
$4.000+76.8% to mean$11.00
# Analysts4
Ownership
Shares Out.63.70M
Float57.01M
Insiders3.48%
Institutions77.53%
Short Interest
Short Ratio8.9d
Short % Float11.97%
Short % Out.11.55%
Shares Short7.34M
Short (prev mo.)6.63M
Technical
SMA 504.222 (-2.9%)
SMA 2002.876 (+42.6%)
Beta1.22
S&P 52W Chg18.16%
Avg Vol (30d)701.20K
Avg Vol (10d)557.86K
Technical Indicators
RSI (14)50.5
MACD-0.0185
MACD Signal-0.0544
MACD Hist.+0.0359
BB Upper4.270 USD
BB Middle3.951 USD
BB Lower3.632 USD
BB Width16.13%
ATR (14)0.2629 USD
Vol Ratio (20d)0.41x